Predictmedix — Investor Presentation (November 2021)
21 slides from Predictmedix's investor presentation, November 2021
Slide 1: Predictmedix
PREDICTMEDIX.COM CSE : PMED OTCQB : PMEDF
Slide 2: Forward-looking statements disclaimer
This presentation may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results of the Company. Such statements involve known and unknown risks, uncertainties and other factors that may cause a
Slide 3: Predictmedix
Predictmedix Predictmedix is a leading provider of rapid health screening and remote patient care solutions globally. The Company’s Safe Entry Stations – powered by a proprietary artificial CSE: PMED - OTCQB: PMEDF intelligence (AI) – use multispectral cameras to analyze physiological data patterns
Slide 4: The Current Landscape
The Current Landscape Workplace COVID-19 & Cannabis & Mental Virtual Infectious Alcohol Illnesses Care Diseases Impairment 4 CSE : PMED OTCQB : PMEDF
Slide 5: Safe Entry Station
SAFE ENTRY STATION Ui). @J PACKED CELEBRITY SUPER BOWL PARTIES DRAWING CRITICISM CSE:PMED OTCQB
Slide 6: Easy to deploy in any indoor and outdoor location
Easy to deploy Infections including COVID-19, produce unique physiological patterns in any indoor and that our solution will detect, assess and determine the probability of that person being infected or not infected. outdoor location Workplaces, Retail, As the virus mutates, our AI will learn how ne
Slide 7: First to Market
Employers, as well as law enforcement, test people for traces of cannabis, alcohol First to Market and opioids. However, they cannot determine if individuals are actually impaired. Without the ability to determine impairment, it is impossible to accurately Predictmedix first-to-market AI product pre
Slide 8: First Diagnostic Tool
Mental illness is difficult to detect at early stages. Primarily due to First Diagnostic Tool a lack of diagnostic tools other than standardized surveys and subjective assessment from trained healthcare practitioners. Predictmedix Mental Illness Diagnostic Screening is a disruptive AI technology tha
Slide 9: Screening as a Service (SaaS)
Screening as a Service (SaaS) Drives High-Margin, Recurring Revenue with Multi-Year Contracts Hardware Deployment Recurring SaaS Fee Multi-Year Contracts $3,500 – 12,000/Unit $1,000 – 3,000/month Our customers invest in our technology not as a reaction to COVID, but with the long-term understanding
Slide 10: The biggest and best believe in our solutions
The biggest and best believe in our solutions Tech Mahindra – India Tier-1 Predictmedix has signed Joint Paras Defence – India Tier-2 Venture agreements with Tech Mahindra, who will resell North American Resellers Predictmedix secured a reseller Predictmedix to their global client agreement with Par
Slide 11: Mainstream, trade, and investor media
Mainstream, trade, and investor media are actively pursuing Predictmedix for interviews and features. 11 CSE : PMED OTCQB : PMEDF
Slide 12: Remote patient monitoring & telehealth platform
Remote patient monitoring & telehealth platform for healthcare, LTC and employers Long Term Care (LTC) Clinical Research Large Scale and Retirement Residences Organizations (CRO) Employees Covid-19 has revealed the devastating Traditional methods of on-site monitoring Existing human resource platfor
Slide 13: Putting care into telehealth
Putting care into telehealth Wearables and Bluetooth Reward Programs Engagement tools Makes it easy for patients to share their Incentivises compliance to From video to multiple communication channels, vitals through the platform, and to give promote better outcomes and patients and practitioners, e
Slide 14: Protecting our Technology in Key Global markets
Protecting our Technology in Key Global markets 6 U.S. PATENTS HAVE BEEN FILED IMPAIRMENT (1) INFECTIOUS DISEASE SYMPTOMS (1) MOBILE WELL-BEING (4) 14 CSE : PMED OTCQB : PMEDF
Slide 15: Management team
Dr. Rahul Kushwah Rakesh Malhotra Nandan Mishra Himanshu Ujjawal Rajiv Muradia Interim CEO CFO Co-AI Lead Singh VP, Operations Co-AI Lead § PhD, Banting Fellow § CPA designation in § Artificial Intelligence § Mobile Wellbeing (one of 23 global US and Canada, FCA pioneer in translational § Specializa
Slide 16: AI powered technologies positioned to eliminate need for biologics
There is a growing need for rapid, mass, early stage § Expand Revenue Base: Large scale commercial rollouts in North America, Europe and India, currently screening for governments, healthcare and employers. in discussion phases § Improve Capabilities: Completion of clinical study with MGM Hospital G
Slide 17: Corporate Information
CSE : PMED OTCQB : PMEDF PREDICTMEDIX.COM CORPORATE INFORMATION 77 King Street West, Suite 3000 Toronto, ON, Canada M5K 2A1 INVESTOR RELATIONS Lucas A. Zimmerman Director – MZ North America (949) 259-4987 PMEDF@mzgroup.us
Slide 18: Competitive Landscape
Competitive Landscape Non- Temperature Multi-Symptom Commercialization Company AI Notes Invasive Detection Detection Stage Potentially introducing more symptom Launching detection Indicates it is AI Enabled which may mean future versions Commercialized will use AI in some fashion Tests air which mea
Slide 19: Competitive Landscape
Competitive Landscape Impairment Commercialization Company AI Non-Invasive Notes Detection Stage Cannabix Breathalyzer Pre-commercialization Hound Marijuana Breathalyzer Unknown how it determines impairment and may rely on amount of cannabinoids to Pre-commercialization apply a rating for potential
Slide 20: Board of Directors
Sheldon Kales Dr. Rahul Kushwah Ajit Kumar Tomas Sipos § Expertise in operations, business § PhD, Banting Fellow § Seasoned healthcare § Seasoned investment banker strategy and capital markets business leader § Developed world’s first genetic § Has held several senior positions, § Held leadership ro
Slide 21: Advisory Board
Advisory MSc, PhD MBBS, MS, DNB Board § Neurosurgeon with over 34 years’ experience in § One of India’s leading thoracic surgeons, practicing in BLK microscopic and minimal invasive neurosurgery Super Speciality Hospital, the largest stand-alone private § Sugita Fellow from Nagoya University, Japan